Case report: pulmonary nocardiosis caused by Nocardia exalbida in an immunocompetent patient

BMC Infect Dis. 2021 Aug 9;21(1):776. doi: 10.1186/s12879-021-06416-w.

Abstract

Background: Nocardiosis is known as an opportunistic infection in immunocompromised hosts, but it occasionally has been reported in immunocompetent patient. The Nocardia exalbida is first-reported in 2006 from Japan, and a few cases of have been reported in only immunocompromised host, and the characteristic is still unclear. We herein describe the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient.

Case presentation: A77 -year-old Japanese man was admitted to our hospital on November 2, 2018. He was a lifelong non-smoker with no childhood history of respiratory disease. He had a medical history of dyslipidemia. One month before this admission fevers, sputum, mild cough were developed and he was evaluated in a clinic near our hospital. His diagnosis was community acquired pneumonia within his right middle lobe. He was treated with ceftriaxone 1 g/day intravenously for a week, however his symptoms relapsed a few days later. So, the physician retried ceftriaxone for another 3 days, but his symptoms did not improve. He was referred to our hospital. He was treated with sitafloxacin as an outpatient for a week, however his symptoms got worse. The chest CT showed consolidation and atelectasis in his right middle lobe. Low density area was scattered in consolidation, and right pleural effusion was observed. The patient was diagnosed with pulmonary abscess and he was admitted. Administration of piperacillin/tazobactam improved his condition. We switched antibiotics to amoxicillin/clavulanate, and he was discharged. After 2 weeks, he relapsed and was admitted again. After administration of piperacillin/tazobactam for 3 weeks, we perform bronchoscopy and Nocardia species were cultured from samples of the bronchial wash. The isolates were identified as N. exalbida using 16S rRNA gene sequencing. We prescribed Trimethoprim / Sulfamethoxazole (TMP/SMX) for 4 months. Then we switched to minocycline for renal dysfunction caused from TMP-SMX for 1 more month. After 5 months therapy, Consolidation on CT disappeared, and Nocardiosis was cured.

Conclusion: we reported the first case of pulmonary nocardiosis caused by N. exalbida in an immunocompetent patient. N. exalbida infection might be associated with a good response to treatment.

Keywords: Immunocompetent patient; Infection; Nocardia exalbida; Pulmonary nocardiosis.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Humans
  • Lung Diseases* / microbiology
  • Male
  • Nocardia Infections* / diagnosis
  • Nocardia Infections* / drug therapy
  • Nocardia* / genetics
  • Nocardia* / pathogenicity
  • RNA, Ribosomal, 16S
  • Trimethoprim, Sulfamethoxazole Drug Combination

Substances

  • RNA, Ribosomal, 16S
  • Trimethoprim, Sulfamethoxazole Drug Combination

Supplementary concepts

  • Nocardia exalbida